Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q1 2024 Earnings Conference
Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q1 2024 Earnings Conference
The following is a summary of the Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript:
以下是Alnylam製藥公司（ALNY）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Alnylam Pharmaceuticals reported Q1 2024 product revenue of $365 million, representing a 32% year-on-year growth.
Gross margin on product sales for the quarter is 85%.
The company ended Q1 2024 with cash, cash equivalents, and marketable securities of $2.4 billion.
Revenues from collaborations for the quarter were $119 million, up by a significant 225% compared to Q1 2023.
They project their 2024 net product revenue guidance to reach between $1.4 billion and $1.5 billion.
Alnylam Pharmicals報告稱，2024年第一季度產品收入爲3.65億美元，同比增長32％。
該季度的產品銷售毛利率爲85％。
截至2024年第一季度，該公司的現金、現金等價物和有價證券爲24億美元。
本季度的合作收入爲1.19億美元，與2023年第一季度相比增長了225％。
他們預計，2024年的淨產品收入預期將達到14億至15億美元。
Business Progress:
業務進展：
Alnylam experienced a robust 77% revenue increase year-over-year for OXLUMO due to increased demand and favorable gross-to-net adjustment.
TTR franchise made significant progress, moving towards reporting top line results from the HELIOS-B Phase 3 study of vutrisiran.
They were successful in the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapy for hypertension.
FDA clearance was received to initiate the multiple dose portion of the Phase 1 study of novel drug, mivelsiran, in early-onset Alzheimer's disease.
Preparations for potential commercial launch of Vutrisiran or AMVUTTRA for cardiomyopathy applications are ongoing, pending positive HELIOS-B outcome results.
The company's Alzheimer's disease drug development program, ALN-APP, continues to make progress with a Phase 2 study expected to start soon.
由於需求增加和有利的總淨調整，Alnylam的收入同比增長了77％。
TTR特許經營權取得了重大進展，正在着手報告Vutrisiran的HELIOS-B三期研究的主要結果。
他們成功完成了對齊萊貝西蘭的 KARDIA-2 二期研究，這是一種治療高血壓的研究性 RNAi 療法。
美國食品藥品管理局批准啓動針對早發性阿爾茨海默氏病的新藥米維西蘭的1期研究的多劑量部分。
在HELIOS-B取得積極結果之前，針對心肌病應用的Vutrisiran或AMVUTTRA可能商業上市的準備工作正在進行中。
該公司的阿爾茨海默病藥物開發計劃ALN-APP繼續取得進展，預計將很快開始一項2期研究。
More details: Alnylam Pharmaceuticals IR
更多詳情： Alnylam 製藥 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。